| Date Filed | Type | Description |
| 08/17/2023 |
4
| Klausner Richard (Director) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Sold 58,020 shares
@ $2.28, valued at
$132.3k
|
|
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
4
| Lang Matthew (Chief Business Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 2,250,000 options to buy
@ $2.31, valued at
$5.2M
|
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
3
| Lang Matthew (Chief Business Officer) has filed a Form 3 on Lyell Immunopharma, Inc. |
| 07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/28/2023 |
4
| Hill Stephen J. (Chief Technical Ops. Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 900,000 options to buy
@ $2.13, valued at
$1.9M
|
|
| 02/28/2023 |
4
| Albertson Tina M. (Chief Medical Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.13, valued at
$1.5M
|
|
| 02/28/2023 |
4
| Lee Gary K. (Chief Scientific Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 600,000 options to buy
@ $2.13, valued at
$1.3M
|
|
| 02/28/2023 |
4
| Thompson Rahsaan (Chief Legal Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 245,000 options to buy
@ $2.13, valued at
$521.9k
|
|
| 02/28/2023 |
4
| Newton Charles W. (CFO) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.13, valued at
$1.5M
|
|
| 02/28/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5% stake in Lyell Immunopharma Inc. |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
4
| Thompson Rahsaan (Chief Legal Officer) has filed a Form 4 on Lyell Immunopharma, Inc.|
Txns:
| Granted 715,000 options to buy
@ $6.91, valued at
$4.9M
|
|
| 10/06/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
3
| Thompson Rahsaan (Chief Legal Officer) has filed a Form 3 on Lyell Immunopharma, Inc. |
|